Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

NCT07741630 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

PROC

Interventions

DRUG: Mirvetuximab soravtansine
DRUG: Suvemcitug

Sponsor

Peking University Third Hospital